Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis
IntroductionDirect antiviral agents (DAAs) have dramatically changed the landscape of liver diseases associated with chronic hepatitis C virus (HCV) infection. However, limited data are available on the antiviral effect of sofosbuvir (SOF) + velpatasvir (VEL) ± ribavirin (RBV), SOF + VEL + voxilapre...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Gastroenterology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgstr.2025.1511150/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856555323293696 |
|---|---|
| author | Liwei Zhuang Liwei Zhuang Junnan Li Yu Zhang Shibo Ji Huichun Xing Huichun Xing |
| author_facet | Liwei Zhuang Liwei Zhuang Junnan Li Yu Zhang Shibo Ji Huichun Xing Huichun Xing |
| author_sort | Liwei Zhuang |
| collection | DOAJ |
| description | IntroductionDirect antiviral agents (DAAs) have dramatically changed the landscape of liver diseases associated with chronic hepatitis C virus (HCV) infection. However, limited data are available on the antiviral effect of sofosbuvir (SOF) + velpatasvir (VEL) ± ribavirin (RBV), SOF + VEL + voxilaprevir (VOX), and glecaprevir (GLE) + pibrentasvir (PIB) in treating patients infected with HCV GT3 in a real-world setting.MethodsUsing the EMBASE, PubMed, and Cochrane Library databases, articles were screened from 1 January 2016 to 1 June 2024. The sustained virologic response (SVR) rates were analyzed using the Freeman–Tukey double arcsine transformation in a random-effects model in R4.1.0 software.ResultsWe recruited 3,177 patients with HCV GT3 in 19 studies from 9 countries. The pooled SVR12/24 rate of the three evaluated regimens was 94.00% (95% CI: 90.87-96.59%). Furthermore, the SVR rate was 83.81% (95% CI: 75.70-90.62%) in patients receiving SOF+VEL+VOX; 94.98% (95% CI: 92.02-97.33%) in patients receiving SOF+VEL ± RBV; and 96.96% (95% CI: 93.20-99.45%) in patients receiving GLE+PIB. The pooled SVR12/24 rate of the three regimens was 95.70% (95% CI: 91.74-98.58%) and 90.50% (95% CI: 83.50-95.90%) in non-cirrhotic and cirrhotic patients, respectively. The pooled SVR rate was 96.79% (95% CI: 93.37-99.13%) and 88.41% (95% CI: 82.67-93.22%) in treatment-naive and treatment-experienced patients, respectively.ConclusionSOF+VEL ± RBV, GLE+PIB, and SOF+VEL+VOX had good antiviral effectiveness for chronic HCV-GT3 infection in real-world settings. Factors such as cirrhosis and treatment experience, especially previous DAA treatment failure, may influence the SVR rate. |
| format | Article |
| id | doaj-art-0c44e8ae90f84a2fae2dd0092b4afc69 |
| institution | Kabale University |
| issn | 2813-1169 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Gastroenterology |
| spelling | doaj-art-0c44e8ae90f84a2fae2dd0092b4afc692025-02-12T07:26:01ZengFrontiers Media S.A.Frontiers in Gastroenterology2813-11692025-02-01410.3389/fgstr.2025.15111501511150Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysisLiwei Zhuang0Liwei Zhuang1Junnan Li2Yu Zhang3Shibo Ji4Huichun Xing5Huichun Xing6Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaMedical Research Group, Peking University Ditan Teaching Hospital, Beijing, ChinaDepartment of Science and Education, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaCenter of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaCenter of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaCenter of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaMedical Research Group, Peking University Ditan Teaching Hospital, Beijing, ChinaIntroductionDirect antiviral agents (DAAs) have dramatically changed the landscape of liver diseases associated with chronic hepatitis C virus (HCV) infection. However, limited data are available on the antiviral effect of sofosbuvir (SOF) + velpatasvir (VEL) ± ribavirin (RBV), SOF + VEL + voxilaprevir (VOX), and glecaprevir (GLE) + pibrentasvir (PIB) in treating patients infected with HCV GT3 in a real-world setting.MethodsUsing the EMBASE, PubMed, and Cochrane Library databases, articles were screened from 1 January 2016 to 1 June 2024. The sustained virologic response (SVR) rates were analyzed using the Freeman–Tukey double arcsine transformation in a random-effects model in R4.1.0 software.ResultsWe recruited 3,177 patients with HCV GT3 in 19 studies from 9 countries. The pooled SVR12/24 rate of the three evaluated regimens was 94.00% (95% CI: 90.87-96.59%). Furthermore, the SVR rate was 83.81% (95% CI: 75.70-90.62%) in patients receiving SOF+VEL+VOX; 94.98% (95% CI: 92.02-97.33%) in patients receiving SOF+VEL ± RBV; and 96.96% (95% CI: 93.20-99.45%) in patients receiving GLE+PIB. The pooled SVR12/24 rate of the three regimens was 95.70% (95% CI: 91.74-98.58%) and 90.50% (95% CI: 83.50-95.90%) in non-cirrhotic and cirrhotic patients, respectively. The pooled SVR rate was 96.79% (95% CI: 93.37-99.13%) and 88.41% (95% CI: 82.67-93.22%) in treatment-naive and treatment-experienced patients, respectively.ConclusionSOF+VEL ± RBV, GLE+PIB, and SOF+VEL+VOX had good antiviral effectiveness for chronic HCV-GT3 infection in real-world settings. Factors such as cirrhosis and treatment experience, especially previous DAA treatment failure, may influence the SVR rate.https://www.frontiersin.org/articles/10.3389/fgstr.2025.1511150/fullreal-world effectivenesssofosbuvir/velpatasvirglecaprevir/pibrentasvirsofosbuvir/velpatasvir/voxilaprevirgenotype 3 HCV |
| spellingShingle | Liwei Zhuang Liwei Zhuang Junnan Li Yu Zhang Shibo Ji Huichun Xing Huichun Xing Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis Frontiers in Gastroenterology real-world effectiveness sofosbuvir/velpatasvir glecaprevir/pibrentasvir sofosbuvir/velpatasvir/voxilaprevir genotype 3 HCV |
| title | Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis |
| title_full | Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis |
| title_fullStr | Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis |
| title_full_unstemmed | Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis |
| title_short | Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis |
| title_sort | real world effectiveness of sofosbuvir velpatasvir glecaprevir pibrentasvir and sofosbuvir velpatasvir voxilaprevir against genotype 3 hepatitis c virus infection a systematic review and meta analysis |
| topic | real-world effectiveness sofosbuvir/velpatasvir glecaprevir/pibrentasvir sofosbuvir/velpatasvir/voxilaprevir genotype 3 HCV |
| url | https://www.frontiersin.org/articles/10.3389/fgstr.2025.1511150/full |
| work_keys_str_mv | AT liweizhuang realworldeffectivenessofsofosbuvirvelpatasvirglecaprevirpibrentasvirandsofosbuvirvelpatasvirvoxilapreviragainstgenotype3hepatitiscvirusinfectionasystematicreviewandmetaanalysis AT liweizhuang realworldeffectivenessofsofosbuvirvelpatasvirglecaprevirpibrentasvirandsofosbuvirvelpatasvirvoxilapreviragainstgenotype3hepatitiscvirusinfectionasystematicreviewandmetaanalysis AT junnanli realworldeffectivenessofsofosbuvirvelpatasvirglecaprevirpibrentasvirandsofosbuvirvelpatasvirvoxilapreviragainstgenotype3hepatitiscvirusinfectionasystematicreviewandmetaanalysis AT yuzhang realworldeffectivenessofsofosbuvirvelpatasvirglecaprevirpibrentasvirandsofosbuvirvelpatasvirvoxilapreviragainstgenotype3hepatitiscvirusinfectionasystematicreviewandmetaanalysis AT shiboji realworldeffectivenessofsofosbuvirvelpatasvirglecaprevirpibrentasvirandsofosbuvirvelpatasvirvoxilapreviragainstgenotype3hepatitiscvirusinfectionasystematicreviewandmetaanalysis AT huichunxing realworldeffectivenessofsofosbuvirvelpatasvirglecaprevirpibrentasvirandsofosbuvirvelpatasvirvoxilapreviragainstgenotype3hepatitiscvirusinfectionasystematicreviewandmetaanalysis AT huichunxing realworldeffectivenessofsofosbuvirvelpatasvirglecaprevirpibrentasvirandsofosbuvirvelpatasvirvoxilapreviragainstgenotype3hepatitiscvirusinfectionasystematicreviewandmetaanalysis |